ATE302269T1 - Ste20-verwandte proteinkinasen - Google Patents

Ste20-verwandte proteinkinasen

Info

Publication number
ATE302269T1
ATE302269T1 AT99918539T AT99918539T ATE302269T1 AT E302269 T1 ATE302269 T1 AT E302269T1 AT 99918539 T AT99918539 T AT 99918539T AT 99918539 T AT99918539 T AT 99918539T AT E302269 T1 ATE302269 T1 AT E302269T1
Authority
AT
Austria
Prior art keywords
ste20
protein kinases
nucleic acid
acid molecules
molecules encoding
Prior art date
Application number
AT99918539T
Other languages
German (de)
English (en)
Inventor
Gregory Plowman
Ricardo Martinez
David Whyte
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE302269T1 publication Critical patent/ATE302269T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99918539T 1998-04-14 1999-04-13 Ste20-verwandte proteinkinasen ATE302269T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8178498P 1998-04-14 1998-04-14
PCT/US1999/008150 WO1999053036A2 (en) 1998-04-14 1999-04-13 Ste20-related protein kinases

Publications (1)

Publication Number Publication Date
ATE302269T1 true ATE302269T1 (de) 2005-09-15

Family

ID=22166386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918539T ATE302269T1 (de) 1998-04-14 1999-04-13 Ste20-verwandte proteinkinasen

Country Status (10)

Country Link
US (5) US6680170B2 (enExample)
EP (1) EP1073723B1 (enExample)
JP (1) JP2002522009A (enExample)
AT (1) ATE302269T1 (enExample)
AU (1) AU3642499A (enExample)
CA (1) CA2369172A1 (enExample)
DE (1) DE69926742T2 (enExample)
DK (1) DK1073723T3 (enExample)
ES (1) ES2248997T3 (enExample)
WO (1) WO1999053036A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078182B1 (en) * 1998-04-14 2006-07-18 Board Of Regents, The University Of Texas System TAO protein kinase polypeptides and methods of use therefor
US6013500A (en) 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
EP1112368A1 (en) * 1998-09-10 2001-07-04 Smithkline Beecham Plc Use of protein kinase kiaa0551 as pharmaceutical
CA2362936A1 (en) * 1999-02-19 2000-08-24 Mcmaster University A caspase activated protein kinase
AU3566200A (en) * 1999-04-01 2000-10-23 Astrazeneca Uk Limited Human signal transduction serine/threonine protein kinase
US6558903B1 (en) * 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
AU6181000A (en) * 1999-07-29 2001-02-19 Chugai Research Institute For Molecular Medicine, Inc. Novel genes encoding protein kinase/protein phosphatase
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6861239B1 (en) 1999-09-20 2005-03-01 New York University Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
WO2001036602A2 (en) * 1999-11-15 2001-05-25 Pharmacia Italia S.P.A. Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
EP1254214A2 (en) * 2000-01-25 2002-11-06 Sugen, Inc. Human protein kinases and protein kinase-like enzymes
EP1385992A2 (en) * 2000-09-20 2004-02-04 Kinetek Pharmaceuticals, Inc. Cancer associated protein kinases and their uses
AU2002243539A1 (en) * 2001-01-12 2002-07-24 Incyte Genomics, Inc. Molecules for disease detection and treatment
US7265214B2 (en) * 2001-10-19 2007-09-04 Rigel Pharmaceuticals, Inc. Germinal center kinase proteins, compositions and methods of use
JP2005518198A (ja) 2001-12-28 2005-06-23 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｐａｋ５関連の組成物及び方法
US7439329B2 (en) * 2002-07-05 2008-10-21 Sugen, Inc. GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof
GB0220770D0 (en) * 2002-09-06 2002-10-16 Ares Trading Sa Proteins
US20050054017A1 (en) * 2002-11-27 2005-03-10 Sugen, Inc. Phosphospecific PAK antibodies and diagnostic kits
AU2003296696A1 (en) * 2002-12-23 2004-07-14 Devgen Nv Kinase sequences
GB2396615A (en) * 2002-12-23 2004-06-30 Devgen Nv Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases
US20040242461A1 (en) * 2003-04-08 2004-12-02 Schneider Michael D. Modulators of telomere stability
DK1653844T3 (da) * 2003-08-13 2013-03-11 Novartis Vaccines & Diagnostic Prionspecifikke peptidreagenser
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
WO2005111234A2 (en) * 2004-05-12 2005-11-24 Sugen, Inc. Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers
NZ587255A (en) * 2005-01-13 2012-03-30 Novartis Vaccines & Diagnostic Elisa assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20090099343A1 (en) * 2005-01-13 2009-04-16 David Peretz Isolation of pathogenic prions
NZ566020A (en) * 2005-09-09 2012-08-31 Novartis Ag Prion-specific peptoid reagents
WO2009134942A1 (en) * 2008-04-30 2009-11-05 Novartis Ag. Assay for pathogenic conformers
KR101219395B1 (ko) * 2010-07-15 2013-01-11 전자부품연구원 리튬이차전지용 양극재료 및 그의 제조방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
DE3069468D1 (en) 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
ATE114661T1 (de) 1990-04-02 1994-12-15 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
EP0654024A1 (en) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5366889A (en) * 1992-11-30 1994-11-22 The General Hospital Corporation DNA encoding a protein-coupled receptor kinase
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5830699A (en) * 1996-05-07 1998-11-03 The General Hospital Corporation SOK-1 and methods of use
AU4448597A (en) 1996-10-04 1998-05-05 Connaught Laboratories Limited Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine
AU8296698A (en) * 1997-07-08 1999-02-08 Cadus Pharmaceutical Corporation (kds) protein kinase molecules and uses related thereto
AU8778698A (en) * 1997-08-11 1999-03-01 Ontogeny, Inc. Serine/threonine kinase, and uses related thereto
GB9719920D0 (en) * 1997-09-19 1997-11-19 Zeneca Ltd Human Ste20-Like Stress Activated Serine/Threonine Kinase
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase

Also Published As

Publication number Publication date
US6680170B2 (en) 2004-01-20
CA2369172A1 (en) 1999-10-21
US20050142625A1 (en) 2005-06-30
WO1999053036A2 (en) 1999-10-21
ES2248997T3 (es) 2006-03-16
DK1073723T3 (da) 2006-01-02
JP2002522009A (ja) 2002-07-23
EP1073723A2 (en) 2001-02-07
WO1999053036A3 (en) 2000-05-11
AU3642499A (en) 1999-11-01
US20030050230A1 (en) 2003-03-13
DE69926742T2 (de) 2006-06-14
EP1073723B1 (en) 2005-08-17
US20040224323A1 (en) 2004-11-11
DE69926742D1 (de) 2005-09-22
US20070072261A1 (en) 2007-03-29
US6656716B1 (en) 2003-12-02
WO1999053036A9 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
DE69926742D1 (de) Ste20-verwandte proteinkinasen
WO2002060955A3 (en) Modified antibodies and methods of use
EA200500053A1 (ru) Способы получения замещённых пиримидинов и производных пиримидинов в качестве ингибиторов протеинкиназ
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2000073469A3 (en) Protein kinases
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
EP1409509A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF C REACTIVE PROTEIN
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
EP1430072A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF CHOLESTERYTERTERTRANSFERPROTEIN
WO2003018600A3 (en) Antisense modulation of microsomal triglyceride transfer protein expression
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO1999066051A3 (en) Nek-related and bub1-related protein kinases
EP1248635A4 (en) ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION
WO2003027229A3 (en) Antisense modulation of rip2 expression
EP1595946A3 (en) STE20-related protein kinases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073723

Country of ref document: EP

REN Ceased due to non-payment of the annual fee